AVTR Quote, Financials, Valuation and Earnings

Azenta has a net margin of 4.08% compared to Avantor's net margin of -28.21%. Avantor's return on equity of 12.61% beat Azenta's return on equity of -3.48%.

Avantor has a consensus price target of $16.98, signalling upside risk potential of 31.56%. On the other hand Azenta has an analysts' consensus of $41.60 which suggests that it could grow by 55.69%. Given that Azenta has higher upside potential than Avantor, analysts believe Azenta is more attractive than Avantor.

Avantor has a beta of 1.088, which suggesting that the stock is 8.795% more volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.6B, which are larger than Azenta quarterly revenues of $143.4M. Avantor's net income of $64.5M is higher than Azenta's net income of -$40.5M. Notably, Avantor's price-to-earnings ratio is 12.41x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.32x versus 2.03x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 4.08% compared to Avantor's net margin of 2.17%. Avantor's return on equity of 12.61% beat Bruker's return on equity of 4.53%.

Avantor has a consensus price target of $16.98, signalling upside risk potential of 31.56%. On the other hand Bruker has an analysts' consensus of $55.13 which suggests that it could grow by 50.22%. Given that Bruker has higher upside potential than Avantor, analysts believe Bruker is more attractive than Avantor.

Avantor has a beta of 1.088, which suggesting that the stock is 8.795% more volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.55% to investors and pays a quarterly dividend of $0.05 per share. Avantor pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avantor quarterly revenues are $1.6B, which are larger than Bruker quarterly revenues of $801.4M. Avantor's net income of $64.5M is higher than Bruker's net income of $17.4M. Notably, Avantor's price-to-earnings ratio is 12.41x while Bruker's PE ratio is 70.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.32x versus 1.61x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 4.08% compared to Avantor's net margin of -231.19%. Avantor's return on equity of 12.61% beat Harvard Bioscience's return on equity of -103.83%.

Avantor has a consensus price target of $16.98, signalling upside risk potential of 31.56%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 542.4%. Given that Harvard Bioscience has higher upside potential than Avantor, analysts believe Harvard Bioscience is more attractive than Avantor.

Avantor has a beta of 1.088, which suggesting that the stock is 8.795% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.6B, which are larger than Harvard Bioscience quarterly revenues of $21.8M. Avantor's net income of $64.5M is higher than Harvard Bioscience's net income of -$50.3M. Notably, Avantor's price-to-earnings ratio is 12.41x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.32x versus 0.22x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Techne has a net margin of 4.08% compared to Avantor's net margin of 7.14%. Avantor's return on equity of 12.61% beat Bio-Techne's return on equity of 6.38%.

Avantor has a consensus price target of $16.98, signalling upside risk potential of 31.56%. On the other hand Bio-Techne has an analysts' consensus of $69.26 which suggests that it could grow by 43.09%. Given that Bio-Techne has higher upside potential than Avantor, analysts believe Bio-Techne is more attractive than Avantor.

Avantor has a beta of 1.088, which suggesting that the stock is 8.795% more volatile than S&P 500. In comparison Bio-Techne has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.876%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Techne offers a yield of 0.66% to investors and pays a quarterly dividend of $0.08 per share. Avantor pays -- of its earnings as a dividend. Bio-Techne pays out 29.99% of its earnings as a dividend. Bio-Techne's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avantor quarterly revenues are $1.6B, which are larger than Bio-Techne quarterly revenues of $316.2M. Avantor's net income of $64.5M is higher than Bio-Techne's net income of $22.6M. Notably, Avantor's price-to-earnings ratio is 12.41x while Bio-Techne's PE ratio is 59.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.32x versus 6.42x for Bio-Techne. Usually stocks with elevated PS ratios are considered overvalued.